The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, ...
The FDA granted RMAT designation to nogapendekin alfa and CAR-NK for reversing lymphopenia in patients with cancer, with ...
Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...
An international student has displayed the messages a man in his 40s sent her on WhatsApp because she rejected him. The messages got many people talking.
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...
Precigen's PRGN-2012 and UltraCAR-Ts offer groundbreaking therapies. Read why PGEN stock is a strong pick, with major ...
In July 2024, announced results of A$55.9 million (US$36.9 million) retail entitlement offer, representing the final stage of the approximately A$227.3 million (US$150.0 million) capital raising ...
Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...
Organogenesis ( ORGO -5.54%) Q4 2024 Earnings Call Feb 27, 2025, 5:00 p.m. ET ...
After a second round, the U.S. FDA has accepted for review radiopharmaceutical company Telix Pharmaceuticals Ltd.’s BLA for ...
The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback